PT  - JOURNAL ARTICLE
AU  - CAMPS, CARLOS
AU  - CABALLERO, CRISTINA
AU  - BLASCO, ANA
AU  - SAFONT, MARIA JOSE
AU  - BERROCAL, ALFONSO
AU  - GARDE, JAVIER
AU  - JUAREZ, ASUNCION
AU  - SIRERA, RAFAEL
AU  - BREMNES, ROY M.
TI  - Weekly Paclitaxel as Second/Third-line Treatment in Advanced Non-small Cell Lung Cancer Patients: Efficacy and Tolerability
DP  - 2005 Nov 01
TA  - Anticancer Research
PG  - 4611--4614
VI  - 25
IP  - 6C
4099  - http://ar.iiarjournals.org/content/25/6C/4611.short
4100  - http://ar.iiarjournals.org/content/25/6C/4611.full
SO  - Anticancer Res2005 Nov 01; 25
AB  - Background: The aim of the present study was to evaluate the efficacy and toxicity of weekly paclitaxel as second- or third-line treatment in non-small cell lung cancer (NSCLC) patients. Materials and Methods: The outcome measured in 37 patients were: response rates, symptom relief (dyspnoea, asthenia and pain), toxicity, overall survival (OS) and time to progression (TTP). Results: Objective response was seen in 8%, stable disease in 27% and disease progression in 62%. Three paclitaxel courses reduced the frequency of WHO grade 2-3 dyspnoea and asthenia from 38% and 43% to 13.5% and 8.1%, respectively. Moderate to severe pain (VAS score 3-8) was reduced from 35.1% to 24.3%. Median OS was 38 weeks and TTP 12 weeks. Haematological toxicity included anaemia (30% grade 2-3) and neutropenia (8% grade 3). Non-haematological toxicity included peripheral neuropathy (41% grade 1-2). Conclusion: In the routine outpatient setting, weekly paclitaxel is feasible, active and well-tolerated as second/third-line chemotherapy in patients with advanced NSCLC. Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved